Clinical Trials Logo

Filter by:
NCT ID: NCT02419872 Completed - Asthma Clinical Trials

Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease

SPRINT
Start date: May 31, 2015
Phase: N/A
Study type: Observational

The study is to evaluate the percentage of patients with asthma or COPD achieving disease control

NCT ID: NCT02419417 Completed - Advanced Tumors Clinical Trials

Study of BMS-986158 in Subjects With Select Advanced Cancers

BET
Start date: June 19, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers

NCT ID: NCT02418806 Completed - Alzheimer's Disease Clinical Trials

Group Therapy for Caregivers of Alzheimer's Disease Patients in Spanish Elderly Persons Centres

cuiDem
Start date: January 2014
Phase: N/A
Study type: Interventional

An experimental study designed to test the effectiveness of a psychological intervention based on group therapy for the caregivers of Alzheimer's disease patients. The intervention consists of 16 sessions of a cognitive-behavioral psychological group therapy. This study aims to demonstrate that Alzheimer's patients' caregivers can decrease the feelings of burden after been involved in a group therapy.

NCT ID: NCT02418585 Completed - Clinical trials for Treatment-resistant Depression

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

TRANSFORM-2
Start date: August 7, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.

NCT ID: NCT02418455 Completed - Clinical trials for Mucopolysaccharidosis

Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

Start date: July 21, 2015
Phase: Phase 2
Study type: Interventional

The primary objective was to evaluate the effect of UX003 treatment in pediatric MPS VII participants less than 5 years of age on safety, tolerability, and efficacy as determined by the reduction of urinary glycosaminoglycans (uGAG) excretion.

NCT ID: NCT02417441 Completed - Fertility Clinical Trials

TiLE (Time Lapse Eeva) Clinical Trial

TiLE
Start date: June 29, 2015
Phase: Phase 4
Study type: Interventional

The purpose of the study was to explore the added value of adjunctive use of Early Embryo Viability Assessment (Eeva) with morphological grading in identifying optimal embryos for transfer.

NCT ID: NCT02416661 Completed - Gaucher Disease Clinical Trials

Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease

LYSO-PROOF
Start date: August 27, 2018
Phase:
Study type: Observational

International, multicenter, epidemiological study to demonstrate the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of naïve, initially non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1 patients and to correlate lyso-Gb1 concentration with the clinical improvement of ERT or SRT treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3

NCT ID: NCT02415959 Completed - Clinical trials for Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis

Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Start date: March 2015
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the efficacy and safety of different doses of Creon Immediate Release (IR) in comparison to Creon® 25,000 Delayed Release/Gastro-Resistant (DR/GR) in subjects with Pancreatic Exocrine Insufficiency (PEI) due to Cystis Fibrosis (CF).

NCT ID: NCT02415400 Completed - Clinical trials for Acute Coronary Syndromes

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Start date: June 4, 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a recent procedure to open up a blood vessel in the heart. All patients would also be taking a class of medicines called P2Y12 inhibitors (such as clopidogrel/Plavix) and be treated for up to 6 months. The primary focus will be a comparison of the bleeding risk of Apixaban, with or without aspirin, versus a Vitamin K antagonist, such as warfarin, with or without aspirin.

NCT ID: NCT02414958 Completed - Clinical trials for Diabetes Mellitus, Type 1

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Start date: June 30, 2015
Phase: Phase 3
Study type: Interventional

Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin regimen of multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Randomisation to 3 treatments arms (equal assignment) following a screening period, an optimisation period and a run-in period. 52 week double-blind treatment period, and 3 week follow-up period.